An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Severe Sickle Cell Disease (SCD) and ST-400 in Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant
Condition: Blood and Lymphatic Diseases Interventions: Drug: BIVV003; Drug: ST-400 Sponsor: Bioverativ, a Sanofi company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Gene Therapy | Genetics | Research | Sickle Cell Anemia | Stem Cell Therapy | Stem Cells | Study | Transplants